Immunotherapy of XXXX with @entity14018 .

@entity1 @entity14018 @entity137 @entity448 @entity1358 @entity1431 @entity3 @entity1011 @entity221
@entity14018 , a double-stranded ribonucleic acid that is a potent inducer of interferon production, was used in a stabilized form to treat 11 @entity1 with @entity1358 . Seven @entity1 completed a full course of 8 infusions at maximum tolerated dosage. All @entity1 experienced transient @entity221 and marked fatigue. @entity448 was mild. Transient @entity1431 occurred in 3 @entity1 and reversible elevation in @entity1011 was observed in 1. All 4 @entity1 with brain @entity3 became lethargic, and 3 died during or shortly after therapy. Only 2 @entity1 demonstrated measurable total regression of isolated @entity3 (pleural/pulmonary in 1 and bone in 1) but in both @entity3 at other sites progressed. No partial regressions were seen. @entity3 at all other sites (liver, brain and renal fossa) progressed during therapy. @entity1 who appeared to respond and who performed best during therapy generally demonstrated a higher performance status initially. Expression of natural @entity137 in in vitro testing did not correlate with a demonstrated response to treatment.
